NCT02675946 2022-01-26CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Curegenix Inc.Phase 1 Unknown72 enrolled
NCT01294826 2015-06-08Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerSwedish Medical CenterPhase 1 Completed20 enrolled